Unknown

Dataset Information

0

Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy.


ABSTRACT: The prognostic value of plasma Epstein-Barr virus (EBV) DNA remains unknown in nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiation therapy (IMRT). We retrospectively reviewed medical records of 584 newly diagnosed patients with nonmetastatic and biopsy-proven NPC treated using IMRT. Plasma EBV DNA concentration was measured before therapy (pre-DNA) and within 1 month of completing therapy (post-DNA) using real-time quantitative polymerase chain reaction. Receiver operating characteristic (ROC) curves were generated to identify pre-DNA and post-DNA cut-off values. Prognostic value was assessed using a multivariate Cox proportional hazards model .Three-year disease-free survival (DFS), overall survival (OS), loco-regional relapse-free survival (LRRFS) and distant metastasis-free (DMFS) for pre-DNA >2010 vs.?2010 were 78.1% vs. 93.6% (P?0 vs.?=?0 were 49.9% vs. 88.5% (P?

SUBMITTER: Peng H 

PROVIDER: S-EPMC4770420 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5029695 | BioStudies
2020-01-01 | S-EPMC7136458 | BioStudies
1000-01-01 | S-EPMC4868751 | BioStudies
2016-01-01 | S-EPMC4772023 | BioStudies
2015-01-01 | S-EPMC4395211 | BioStudies
2016-01-01 | S-EPMC4838936 | BioStudies
2020-01-01 | S-EPMC7294474 | BioStudies
2017-01-01 | S-EPMC5381175 | BioStudies
2017-01-01 | S-EPMC5546817 | BioStudies
1000-01-01 | S-EPMC6056955 | BioStudies